- Trials with a EudraCT protocol (171)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
171 result(s) found for: Biological target.
Displaying page 7 of 9.
EudraCT Number: 2016-000842-79 | Sponsor Protocol Number: IJB-PROS-PROSPERO-2016 | Start Date*: 2016-09-08 | ||||||||||||||||
Sponsor Name:Institut Jules Bordet | ||||||||||||||||||
Full Title: Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management The ProsPERo Trial | ||||||||||||||||||
Medical condition: Males 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on pall... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001921-25 | Sponsor Protocol Number: CA163115 | Start Date*: 2006-12-19 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer. | |||||||||||||
Medical condition: Locally Recurrent or Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001534-42 | Sponsor Protocol Number: TrRaMM4Gy | Start Date*: 2011-10-21 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Treosulfan and 4 Gy TBI based conditioning with Rapamycin-based GvHD prophylaxis for allogeneic stem cell transplantation in patients with haematological malignancies | |||||||||||||
Medical condition: Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched fa... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004742-42 | Sponsor Protocol Number: IFCT-1802 | Start Date*: 2019-08-29 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 t... | ||||||||||||||||||
Medical condition: Patient with a non small cell lung cancer and a poor general status | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003037-28 | Sponsor Protocol Number: TOPIRA | Start Date*: 2019-10-02 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs. | |||||||||||||
Medical condition: RA patients with active RA despite treatment with DMARDs. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003921-51 | Sponsor Protocol Number: BOT112-03 | Start Date*: 2021-02-11 | |||||||||||
Sponsor Name:Highlight Therapeutics | |||||||||||||
Full Title: Phase 2 single arm clinical study to evaluate the efficacy and safety of intratumoral administration of BO-112 in combination with pembrolizumab in subjects that have progressed on anti-PD-1-based ... | |||||||||||||
Medical condition: Advanced melanoma after progression to immunotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001271-38 | Sponsor Protocol Number: LT 2004 09 | Start Date*: 2006-06-23 |
Sponsor Name:Our Lady's Hospital for Sick Children | ||
Full Title: Intensified pre-operative chemotherapy and radical surgery for HIGH RISK HEPATOBLASTOMA SIOPEL 4 | ||
Medical condition: Hepatoblastoma | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IE (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002066-24 | Sponsor Protocol Number: PrE0204 | Start Date*: 2015-08-28 |
Sponsor Name:The All Ireland Cooperative Oncology Research Group (ICORG) | ||
Full Title: A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma | ||
Medical condition: Advanced or metastatic cholangiocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004330-24 | Sponsor Protocol Number: H3E-MC-S104 | Start Date*: 2009-02-20 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
Full Title: A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage... | ||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) NL (Completed) ES (Completed) IT (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005097-31 | Sponsor Protocol Number: CA182-025 | Start Date*: 2008-08-19 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras wild type Subjects with Metastatic Colorectal Cancer. Revised Protocol... | |||||||||||||
Medical condition: Patients with advanced metastatic colorectal cancer (MCRC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003452-21 | Sponsor Protocol Number: BRF117277 | Start Date*: 2014-01-27 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. | |||||||||||||
Medical condition: Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000208-25 | Sponsor Protocol Number: SYR-322_309 | Start Date*: 2018-03-28 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001796-14 | Sponsor Protocol Number: CYTB323G12101 | Start Date*: 2023-03-20 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE). | |||||||||||||
Medical condition: Systemic Lupus Erythematosus Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001044-54 | Sponsor Protocol Number: Bosupeg | Start Date*: 2018-10-04 |
Sponsor Name:St Olavs Hospital -Trondheim University Hospital | ||
Full Title: A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL | ||
Medical condition: Chronic myeloid leukemia at diagnosis-chronich phase | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002514-32 | Sponsor Protocol Number: NPT-CL-01 | Start Date*: 2018-09-12 | |||||||||||
Sponsor Name:NeuroproteXeon, Inc. | |||||||||||||
Full Title: XePOHCAS: Prospective, randomized, multicenter, interventional trial in adult subjects with out-of-hospital cardiac arrest (OHCA) comparing treatment with standard-of-care post-cardiac arrest inten... | |||||||||||||
Medical condition: Post-cardiac arrest syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004225-26 | Sponsor Protocol Number: GS-US-183-0145 | Start Date*: 2008-08-13 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Backgrou... | |||||||||||||
Medical condition: Human Innunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) PT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000578-20 | Sponsor Protocol Number: CLDK378A2205 | Start Date*: 2015-03-16 | |||||||||||||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||||||||||||
Full Title: A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to ... | |||||||||||||||||||||||
Medical condition: Non-small cell lung cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003058-10 | Sponsor Protocol Number: IBCSG_42-12/BIG_2-12 | Start Date*: 2013-04-03 | |||||||||||
Sponsor Name:International Breast Cancer Study Group (IBCSG) | |||||||||||||
Full Title: A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer | |||||||||||||
Medical condition: Patients with histologically or cytologically confirmed HER2-negative metastatic (stage IV) breast cancer who have not received chemotherapy for metastatic breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) SI (Completed) IE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000307-17 | Sponsor Protocol Number: DIAN-TU-001 | Start Date*: 2014-01-08 |
Sponsor Name:Washington University in St. Louis | ||
Full Title: A Phase II/III randomized, double-blind, placebo-controlled, cognitive endpoint, multicenter study of potential disease modifying therapies in individuals at risk for and with dominantly inherited ... | ||
Medical condition: Dominantly Inherited Alzheimer Disease (DIAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) ES (Temporarily Halted) DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002841-39 | Sponsor Protocol Number: GINECO-OV-222 | Start Date*: 2013-10-07 | |||||||||||
Sponsor Name:ARCAGY GINECO | |||||||||||||
Full Title: A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with rela... | |||||||||||||
Medical condition: Patients with an histologically confirmed diagnosis of ovarian sex-cord stromal tumor in relapse after a platinum-based chemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
